Problems › Should We Enter a New Market? › Law Firms
Revenue potential in a new practice group is the easy half. Whether existing equity partners can transfer their realisation and utilisation is the half that decides the outcome. For law firms, this shows up in a particular place. The numbers that carry the answer are 82 % realisation and 68 % utilisation, and the complication specific to this industry is that 19 of 28 equity partners aged 55 or over with no formal lateral hire programme or associate-to-partner track for eight years. The general version of this problem and the one you are actually in have different first moves.
Revenue potential in a new practice group is the easy half. Whether existing equity partners can transfer their realisation and utilisation is the half that decides the outcome. For law firms, this shows up in a particular place. The numbers that carry the answer are 82 % realisation and 68 % utilisation, and the complication specific to this industry is that 19 of 28 equity partners aged 55 or over with no formal lateral hire programme or associate-to-partner track for eight years. The general version of this problem and the one you are actually in have different first moves.
New practice groups get evaluated on potential fee income, both of which are knowable and neither of which predicts success. The predictive question is what you already have that transfers — a client relationship held by an equity partner, a route to maintain utilisation across fee earners, a cost position tied to lock-up days — and what has to be built from nothing, given no associate-to-partner track.
A practice group can show strong revenue forecasts and still be a bad idea for these equity partners specifically. The reverse is also true: a low-growth area where the firm already achieves 82 per cent realisation will usually outperform an expanding one where every new matter starts with the same lock-up days as competitors.
The other discipline is a stated kill criterion before entry, because practice group expansions are unusually good at consuming partner time quietly for years on the argument that realisation is nearly at target.
These three together are the signature. One on its own usually points somewhere else.
✓ Discussions rest mainly on the £24.8 m revenue split across the five groups and growth estimates for a sixth.
✓ No equity partner has written down the utilisation or lock-up threshold that would trigger exit.
✓ The existing five groups show 68 per cent utilisation and the new group is being asked to lift profit per equity partner.
The move that usually makes it worse. Entering a sixth practice group because profit per equity partner has stalled at £184 k, which takes equity partner time away from the succession issue that actually needs it.
It is for you if you run or finance a law firm and the case rests mainly on market size and growth rate. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a law firm. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Ashgrove Legal LLP, a sample company profile used for testing rather than a customer — £24.8 m gross revenue from five practice groups.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Scale the only practice hitting 88 % realisation to fund its own growth and close the succession gap.
| Investment required | £240 k (remaining FY2026 discretionary cap after £180 k IT commitment) |
| Expected return | 1.4–1.6× cash-on-cash within 24 months at current realisation rates. |
| Revenue, year 1 | £25.4–25.7 m firm-wide (+£0.6–0.9 m incremental) |
| Revenue, year 2 | £26.5–27.1 m firm-wide (+£1.1–1.3 m incremental from B&F segment) |
| Revenue, year 3 | £27.8–28.6 m firm-wide (+£1.3–1.5 m incremental) |
| Exit criteria | Strategy must be reversed if, within 18 months, segment revenue has not reached £2.4 m annualised OR cumulative net profit contribution is below £150 k, OR if any lateral hire’s personal billings fall below 1 200 hours in any rolling 6-month period. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Market Entry & Expansion Strategy, one of 29 engagements the platform runs. For law firms it works through 82 % realisation, 68 % utilisation, £184 k profit per equity partner and 112 lock-up days, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
List what you already own that the new market values, and what a credible incumbent there owns that you do not. If the second list is longer and includes anything structural — distribution, regulation, data depth — entry is a build, not an extension.
Set the number before you start, and treat exceeding it as the kill criterion rather than as a reason to invest more. Most failed entries were never killed, only slowly starved.
Whichever reuses more of what you already have. Geography usually reuses the product and rebuilds distribution; a new segment usually reuses distribution and rebuilds the product. Whichever rebuild is smaller is the safer bet.
Materially, yes. 19 of 28 equity partners aged 55 or over with no formal lateral hire programme or associate-to-partner track for eight years — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are 82 % realisation, 68 % utilisation, £184 k profit per equity partner, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on 82 % realisation and 68 % utilisation. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית